Literature DB >> 10782831

Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis.

T Pincus1, C Swearingen, P Cummins, L F Callahan.   

Abstract

OBJECTIVE: To analyze results of treatment of osteoarthritis (OA) with acetaminophen and the nonsteroidal antiinflammatory drugs (NSAID) through a patient survey.
METHODS: A 15 minute telephone survey was conducted with 300 patients, including 172 with confirmed OA.
RESULTS: Twenty-four percent of patients who took acetaminophen rated it as "very helpful," compared to 31% for ibuprofen, 30% for naproxen, and 56% for diclofenac. Drug continuation beyond 24 months was reported by 33% of patients for acetaminophen, 21% for ibuprofen, 17% for naproxen, and 19% for diclofenac. Acetaminophen was significantly less likely to be discontinued because of toxicity than NSAID. Patients who indicated that they would not take a drug again, and therefore be unlikely to participate in a clinical trial involving this drug, were 26% for acetaminophen, 40% for ibuprofen, 38% for naproxen, and 28% for diclofenac. About 30% of patients who took acetaminophen reported concurrent use of ibuprofen, naproxen, or diclofenac. Among the 67% of patients who identified a drug as "most helpful," 80% named an NSAID, compared to 20% who named acetaminophen or another analgesic as the "most helpful" drug.
CONCLUSION: Patients take many different drugs for OA, most of which are not continued beyond 2 years. Many patients take both acetaminophen and an NSAID. Most patients who identified a drug as "most helpful" named an NSAID rather than acetaminophen or an analgesic drug. These findings may be of value in further development of management strategies and guidelines for OA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10782831

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  25 in total

1.  Key questions concerning paracetamol and NSAIDs for osteoarthritis.

Authors:  P Courtney; M Doherty
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

2.  Global treatment of osteoarthritis.

Authors:  George E Ehrlich
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

Review 3.  Managing osteoarthritis.

Authors:  Shirley P Yu; David J Hunter
Journal:  Aust Prescr       Date:  2015-08-03

Review 4.  Acetaminophen for osteoarthritis.

Authors:  T E Towheed; L Maxwell; M G Judd; M Catton; M C Hochberg; G Wells
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 5.  Osteoarthritis.

Authors:  David J Hunter; David T Felson
Journal:  BMJ       Date:  2006-03-18

6.  Practice guidelines for pharmacists: The management of osteoarthritis.

Authors:  Jason Kielly; Erin M Davis; Carlo Marra
Journal:  Can Pharm J (Ott)       Date:  2017-05-01

7.  Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis.

Authors:  T Pincus; G Koch; H Lei; B Mangal; T Sokka; R Moskowitz; F Wolfe; A Gibofsky; L Simon; S Zlotnick; J G Fort
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

8.  A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee.

Authors:  M Bianchi; M Broggini
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Applying the evidence in osteoarthritis: strategies for pain management.

Authors:  Edward C Huskisson
Journal:  Clin Drug Investig       Date:  2007-12       Impact factor: 2.859

Review 10.  Pharmacological treatments for persistent non-malignant pain in older persons.

Authors:  Thorsten Nikolaus; Andrej Zeyfang
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.